On Nov 9, 2021 Mekonos closed a Series A round and raised $25,000,000 from Debiopharm Innovation Fund, Elementum Ventures, Fiscus Ventures, Novartis, PEAK6 Investments, Reimagined Ventures, Sands Capital, Section 32, TDK Ventures, featuring lead investors Fiscus Ventures, PEAK6 Investments, Reimagined Ventures.

About the company: Mekonos is located at United States, North America.
“Mekonos is creating a proprietary cell-engineering platform, using scalable
silicon technology, for hyper-precise ex vivo delivery of molecules into
any type of cell.”

Company website: http://www.mekonos.com